OpenEvidence, often described as the “ChatGPT for doctors,” has raised $200 million at a $6 billion valuation. Led by Google Ventures, the round saw participation from major venture capital firms like Sequoia Capital, Kleiner Perkins, and Blackstone. Founded just three years ago, OpenEvidence has quickly become a very critical tool for doctors and healthcare professionals across thousands of medical centers.
Since its founding by Daniel Nadler and Zachary Ziegler, OpenEvidence has leveraged advanced natural language processing to synthesize vast amounts of medical research, including peer-reviewed journals like the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine.
This specialization allows clinicians to receive concise, well-referenced clinical answers quickly, removing the time-consuming manual search for information amid an overwhelming volume of medical literature that doubles every 73 days.
The platform has seen explosive adoption, with monthly clinical consultations soaring from 8.5 million in July 2025 to 15 million by October 2025, equivalent to nearly 500,000 queries daily. More than 40% of U.S. physicians reportedly use the platform daily across over 10,000 healthcare facilities, cementing OpenEvidence’s role as an indispensable bedside AI assistant.
“It’s reaching verb-like status among clinicians. OpenEvidence is fundamentally shifting how doctors interact with medical knowledge and apply it in real-time patient care,” said Sangeen Zeb, Partner at Google Ventures.
Innovating the Decision Process
OpenEvidence’s AI is uniquely trained to provide evidence-backed insights, ensuring clinicians receive up-to-date and highly reliable information while minimizing “hallucination” of inaccurate responses which are common in generalist AI chatbots. The platform supports real-time clinical decision making by distilling complex research into actionable guidance that integrates into physician workflows.
Additionally, OpenEvidence recently introduced AI agents such as DeepConsult, designed to autonomously analyze hundreds of peer-reviewed studies and produce comprehensive research syntheses within hours. This is an immense acceleration over traditional months-long medical review processes. The system supplements clinicians’ expertise by providing a “digital twin” of a Ph.D.-level medical researcher.
Unlike traditional healthcare IT platforms, OpenEvidence offers its tool free to verified medical professionals, driving rapid user growth fueled by an advertising-supported model rather than direct institutional billing.
OpenEvidence has garnered significant interest and capital from premier venture firms such as Sequoia Capital, Kleiner Perkins, Blackstone, and Thrive Capital, raising approximately half a billion dollars since its inception. The latest infusion supports scaling computing resources, AI model training, and global marketing initiatives.
Founder Daniel Nadler sees OpenEvidence evolving beyond a search and decision-support platform toward becoming a medical superintelligence that continually learns from the vast dataset generated by clinical interactions. The system aims to actively contribute to advancing medical science by identifying emerging trends and improving patient outcomes at scale, similar to how Google Street View revolutionized geographic mapping.
